SG Americas Securities
EGRX

SG Americas Securities’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

SG Americas Securities’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,971
Closed -$226K – 3348
2023
Q1 		$226K Buy
+7,971
New +$237K ﹤0.01% 2334
2022
Q4 		– Sell
-9,133
Closed -$241K – 3451
2022
Q3 		$241K Sell
9,133
-69
-0.7% -$2.53K ﹤0.01% 2162
2022
Q2 		$409K Sell
9,202
-15,496
-63% -$712K ﹤0.01% 2137
2022
Q1 		$1.22M Buy
24,698
+3,905
+19% +$187K 0.01% 1276
2021
Q4 		$1.06M Sell
20,793
-32,095
-61% -$1.66M 0.01% 1604
2021
Q3 		$2.95M Buy
52,888
+5,723
+12% +$282K 0.01% 947
2021
Q2 		$2.02M Sell
47,165
-8,906
-16% -$368K 0.01% 1117
2021
Q1 		$2.34M Sell
56,071
-4,032
-7% -$187K 0.01% 949
2020
Q4 		$2.8M Buy
60,103
+37,162
+162% +$1.74M 0.01% 862
2020
Q3 		$975K Sell
22,941
-33,488
-59% -$1.46M 0.01% 1192
2020
Q2 		$2.71M Buy
56,429
+20,193
+56% +$1.01M 0.02% 647
2020
Q1 		$1.67M Buy
36,236
+15,047
+71% +$755K 0.02% 920
2019
Q4 		$1.27M Buy
21,189
+12,639
+148% +$754K 0.01% 1102
2019
Q3 		$484K Buy
+8,550
New +$481K ﹤0.01% 1904
2019
Q2 		– Sell
-2,507
Closed -$127K – 3497
2019
Q1 		$127K Sell
2,507
-5,288
-68% -$235K ﹤0.01% 2895
2018
Q4 		$314K Buy
+7,795
New +$402K ﹤0.01% 2137
2018
Q3 		– Sell
-7,046
Closed -$533K – 3512
2018
Q2 		$533K Sell
7,046
-3,989
-36% -$251K ﹤0.01% 1960
2018
Q1 		$581K Buy
11,035
+3,650
+49% +$212K ﹤0.01% 1771
2017
Q4 		$395K Buy
7,385
+2,874
+64% +$160K ﹤0.01% 1992
2017
Q3 		$269K Buy
4,511
+1,706
+61% +$103K ﹤0.01% 2342
2017
Q2 		$221K Sell
2,805
-217
-7% -$17.7K ﹤0.01% 2351
2017
Q1 		$251K Sell
3,022
-3,738
-55% -$278K ﹤0.01% 2280
2016
Q4 		$536K Buy
6,760
+4,385
+185% +$319K ﹤0.01% 1652
2016
Q3 		$166K Buy
+2,375
New +$132K ﹤0.01% 2646
2015
Q4 		– Sell
-1,953
Closed -$145K – 3036
2015
Q3 		$145K Buy
+1,953
New +$162K ﹤0.01% 1643

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG Americas Securities's EGRX Position: Q2 2023 in Review

SG Americas Securities sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 7,971 shares — an estimated $226K sold.

SG Americas Securities first reported a position in EGRX in Q3 2015 and held it in 25 quarters. The position peaked at $2.95M in Q3 2021. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • SG Americas Securities reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • SG Americas Securities sold 7,971 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $226K.
  • SG Americas Securities first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 25 quarters.
  • SG Americas Securities's Eagle Pharmaceuticals, Inc. position peaked at $2.95M in Q3 2021.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on SG Americas Securities's 13F filing for Q2 2023, filed 10 Jul 2023.